Opendata, web and dolomites

SAFER SIGNED

Selective Agonists For Serotonin Receptors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SAFER project word cloud

Explore the words cloud of the SAFER project. It provides you a very rough idea of what is the project "SAFER" about.

community    generate    therapeutic    resource    experiments    industry    subsequently    interpret    max    selectivity    market    ht2a    first    job    transferrable    services    disorders    understand    mastered    move    intersectoral    insights    gain    biased    computational    timing    sweden    crystallographic    primary    data    expertise    university    guide    serotonin    crystal    arming    synchrotron    pharmacology    demand    complementary    business    giving    mechanisms    ample    fundamental    esrs    lund    complementarity    building    cross    ligands    smes    drugs    society    phd    models    scientific    skills    receptor    advantage    safer    innovation    opportune    coupled    pharmaceuticals    crystals    seek    students    protein    biological    gpcrdb    ultimate    crystallography    translate    basic    sustainability    active    few    location    databases    obtain    cns    treatments    groups    construct    commercial    world    mechanistic    worldwide    competitive    receptors    interdisciplinary    train    public    molecular    hallucinogens    signalling    structures   

Project "SAFER" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.safer-itn.eu/
 Total cost 1˙286˙630 €
 EC max contribution 1˙286˙630 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2017
 Funding Scheme MSCA-ITN-EID
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 290˙081.00
2    SAROMICS BIOSTRUCTURES AB SE (Lund) participant 512˙670.00
3    ENAMINE LIMITED LIABILITY COMPANY,RESEARCH AND PRODUCTION ENTERPRISE UA (KYIV) participant 483˙878.00

Map

 Project objective

SAFER will train 5 ESRs, PhD students, to obtain ample scientific, business and transferrable skills, arming them with the expertise to translate knowledge into products and services with importance for European industry and society. All ESRs will first train together at one university to develop complementary skills and basic research data; and subsequently move to two SMEs for applied and commercial research.

The ultimate scientific goal for the SAFER program is to gain molecular understanding and improve selectivity in treatments of CNS-related disorders. This will be done through an interdisciplinary and intersectoral approach, building on a strong complementarity between partners, with a particular focus on the serotonin 5-HT2A receptor – the primary target for many pharmaceuticals and hallucinogens. SAFER will generate and cross-interpret pharmacology and crystallographic data, and construct computational mechanistic models and databases that can explain and guide its experiments. Thus, SAFER will gain new insights into molecular mechanisms that are fundamental to understand the biological and therapeutic effects, and to develop safer drugs. SAFER ESRs will be highly competitive on the job market and much in demand. In particular, crystallography and biased signalling pharmacology of G protein-coupled receptors (e.g. 5-HT2A) are new and highly active research fields, today mastered by only a very few research groups worldwide. The timing and location of SAFER are particularly opportune, taking advantage of the new synchrotron MAX IV in Lund, Sweden, which is world leading for the study of challenging crystals. SAFER will seek to exploit innovation opportunities from novel molecular mechanisms, ligands, and crystal structures. The results will be integrated into a public community resource, GPCRdb, giving a unique potential to achieve community impact and long-term sustainability.

 Deliverables

List of deliverables.
2nd report on dissemination activities Documents, reports 2019-10-03 18:10:31
SAFER web site Websites, patent fillings, videos etc. 2019-07-24 18:15:34
1st report on dissemination activities Documents, reports 2019-07-24 18:15:34

Take a look to the deliverables list in detail:  detailed list of SAFER deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

ApPEARS (2019)

Appearance Printing - European Advanced Research School

Read More